СОЛИНГЕР Алан (US),БАУЕР Роберт Дж. (US),СКАННОН Патрик Дж. (US),АЛЛЕВА Давид (US)
申请号：
RU2015114923
公开号：
RU2015114923A
申请日:
2015.04.21
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. A method of treating type 2 diabetes or a disease caused by type 2 diabetes in humans, comprising administering to a person an antibody to IL-1β or a fragment thereof, wherein said disease caused by type 2 diabetes is a kidney disease, and wherein said antibody or fragment thereof binds to human IL-1β with a dissociation constant of approximately 250 pM or less. 2. A method according to claim 1, characterized in that after the introduction of an initial dose of the indicated antibody or antibody fragment, one or more subsequent doses are administered. A method according to claim 2, characterized in that after the introduction of an initial dose of the indicated antibody or antibody fragment, two or more subsequent doses are administered. A method according to claim 2, characterized in that said initial dose and each one or more subsequent doses are separated from each other by an interval of at least about 2 weeks. The method of claim 2, wherein said initial dose and each one or more subsequent doses are separated from each other by an interval of at least about 1 month. A method according to claim 2, characterized in that said initial dose and each one or more subsequent doses are separated from each other by an interval of at least about 3 months. A method according to claim 2, characterized in that said initial dose and each one or more subsequent doses are separated from each other by an interval of at least about 6 months. A method according to claim 2, characterized in that said initial dose and each (one or more) subsequent dose are separated from each other by an interval of at least about 12 months. The method according to p. 1, characterized in that after the introduction of the initial dose of the specified1. Способ лечения у людей диабета 2-го типа или заболевания, вызванного диабетом 2-го типа, включающий введение человеку антитела к IL-1β или его фрагмента, где указанное заболевание, вызванное диабетом 2-го типа, представляет собой заболевание почек
